Morgan Stanley
AERI

Morgan Stanley’s Aerie Pharmaceuticals AERI Stock Holding History

Morgan Stanley’s Portfolio AERI Stock Details AERI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-1,319,893
Closed -$20M – 8105
2022
Q3 		$20M Sell
1,319,893
-671,191
-34% -$7.8M ﹤0.01% 2193
2022
Q2 		$14.9M Sell
1,991,084
-1,156,985
-37% -$8.15M ﹤0.01% 2608
2022
Q1 		$28.6M Sell
3,148,069
-883,486
-22% -$6.81M ﹤0.01% 1751
2021
Q4 		$28.3M Buy
4,031,555
+1,811,319
+82% +$19M ﹤0.01% 1799
2021
Q3 		$25.3M Buy
2,220,236
+355,606
+19% +$5.2M ﹤0.01% 1843
2021
Q2 		$29.9M Buy
1,864,630
+121,148
+7% +$2.08M ﹤0.01% 1738
2021
Q1 		$31.2M Sell
1,743,482
-4,966
-0.3% -$85.8K ﹤0.01% 1536
2020
Q4 		$23.6M Buy
1,748,448
+268,280
+18% +$3.24M ﹤0.01% 1649
2020
Q3 		$17.4M Buy
1,480,168
+244,207
+20% +$2.97M ﹤0.01% 1582
2020
Q2 		$18.2M Buy
1,235,961
+510,854
+70% +$7.56M ﹤0.01% 1481
2020
Q1 		$9.79M Sell
725,107
-106,512
-13% -$2.02M ﹤0.01% 1803
2019
Q4 		$20.1M Buy
831,619
+68,211
+9% +$1.41M ﹤0.01% 1655
2019
Q3 		$14.7M Buy
763,408
+239,568
+46% +$5.49M ﹤0.01% 1760
2019
Q2 		$15.5M Buy
523,840
+14,928
+3% +$575K ﹤0.01% 1721
2019
Q1 		$24.2M Buy
508,912
+61,976
+14% +$2.73M 0.01% 1320
2018
Q4 		$16.1M Buy
446,936
+80,670
+22% +$3.78M ﹤0.01% 1650
2018
Q3 		$22.5M Sell
366,266
-101,034
-22% -$6.49M 0.01% 1578
2018
Q2 		$31.6M Sell
467,300
-319,670
-41% -$17.9M 0.01% 1217
2018
Q1 		$42.7M Buy
786,970
+218,550
+38% +$12.2M 0.01% 1017
2017
Q4 		$34M Buy
568,420
+468,408
+468% +$28.4M 0.01% 1231
2017
Q3 		$4.86M Sell
100,012
-38,668
-28% -$2.11M ﹤0.01% 2994
2017
Q2 		$7.29M Buy
138,680
+46,056
+50% +$2.14M ﹤0.01% 2462
2017
Q1 		$4.2M Sell
92,624
-34,577
-27% -$1.54M ﹤0.01% 3042
2016
Q4 		$4.82M Buy
127,201
+66,015
+108% +$2.5M ﹤0.01% 3035
2016
Q3 		$2.31M Buy
61,186
+17,470
+40% +$385K ﹤0.01% 3380
2016
Q2 		$769K Buy
43,716
+19,492
+80% +$316K ﹤0.01% 4167
2016
Q1 		$294K Buy
24,224
+12,744
+111% +$202K ﹤0.01% 4757
2015
Q4 		$280K Sell
11,480
-30,682
-73% -$716K ﹤0.01% 4900
2015
Q3 		$748K Sell
42,162
-34,041
-45% -$617K ﹤0.01% 4342
2015
Q2 		$1.34M Buy
76,203
+11,456
+18% +$210K ﹤0.01% 3971
2015
Q1 		$2.03M Buy
64,747
+47,990
+286% +$1.39M ﹤0.01% 3576
2014
Q4 		$490K Sell
16,757
-2,735
-14% -$69.4K ﹤0.01% 4679
2014
Q3 		$403K Buy
19,492
+10,960
+128% +$216K ﹤0.01% 4709
2014
Q2 		$212K Buy
8,532
+3,568
+72% +$61.8K ﹤0.01% 5124
2014
Q1 		$105K Sell
4,964
-17,374
-78% -$351K ﹤0.01% 5431
2013
Q4 		$400K Buy
+22,338
New +$291K ﹤0.01% 4608

Morgan Stanley's AERI Position: Q4 2022 in Review

Morgan Stanley sold out of Aerie Pharmaceuticals (AERI) in Q4 2022, closing a stake of 1,319,893 shares — an estimated $20M sold.

Morgan Stanley first reported a position in AERI in Q4 2013 and held it in 36 quarters. The position peaked at $42.7M in Q1 2018. 0 funds tracked by Wall St. Rank hold AERI as of Q4 2022.

  • Morgan Stanley reported no remaining Aerie Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • Morgan Stanley sold 1,319,893 Aerie Pharmaceuticals shares in Q4 2022, an estimated $20M.
  • Morgan Stanley first reported a position in Aerie Pharmaceuticals in Q4 2013 and held it in 36 quarters.
  • Morgan Stanley's Aerie Pharmaceuticals position peaked at $42.7M in Q1 2018.
  • 0 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q4 2022.

Based on Morgan Stanley's 13F filing for Q4 2022, filed 14 Feb 2023.